Vascepa® (icosapent ethyl) is indicated to reduce the risk of cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization or hospitalization for unstable angina) in statin-treated patients with elevated triglycerides, who are at high risk of cardiovascular events due to:

- established cardiovascular disease, or
- diabetes, and at least one other cardiovascular risk factor

Clinical use:
Not indicated for pediatric use.
Use in geriatrics is not associated with differences in safety or effectiveness, but greater sensitivity of some older individuals cannot be ruled out.

Relevant warnings and precautions:

- Not recommended in combination with or substituted for other products that contain omega-3 fatty acids
- Increased incidence of bleeding
- Caution in patients with known hypersensitivity to fish and/or shellfish
- Periodic monitoring of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels in patients with hepatic impairment is recommended during therapy with Vascepa®
- Fertility
- Not recommended in pregnancy and nursing

For more information:
Please consult the Vascepa® Product Monograph at https://health-products.canada.ca/dpd-bdp/index-eng.jsp for important information relating to adverse reactions, drug interactions, and dosing.

A placebo-controlled trial with a 4.9-year median follow-up of statin-treated adult patients with elevated triglycerides and a high risk of cardiovascular events due to established cardiovascular disease or diabetes with at least 1 other CV risk factor.

Vascepa® demonstrated a significant 25% reduction (event n=705 vs. 901) in time to first occurrence of cardiovascular death, MI, stroke, coronary revascularization or hospitalization for unstable angina (5-point MACE) vs. placebo (1st endpoint). There was no statistically significant difference in risk between the Vascepa® and placebo groups for all-cause mortality.

Consider Vascepa®: The first and ONLY icosapent ethyl (IPE) prescription medication

To learn more, visit www.vascepa.ca